Latest Cinclus Pharma News & Updates

See the latest news and media coverage for Cinclus Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Cinclus Pharma

Clinical-stage pharmaceutical company developing gastric acid disease treatments

cincluspharma.com

Headquarters: Stockholm, Sweden
Founded year: 2014
Company type: Private company
Number of employees: 2–30
Industry: Pharmaceuticals

Last updated Today

Latest news about Cinclus Pharma

In short: Cinclus Pharma completed treatments in its Phase III HEEALING1 study for erosive GERD, with topline results expected in late 2026.

Company announcements

September 2 Cinclus Pharma

Cinclus Pharma completes HEEALING1 study treatment period

The sponsor conducts four week safety evaluations before compiling the clinical dataset for the scheduled fourth quarter analysis.

August 7 Cinclus Pharma

Cinclus Pharma signs licensing agreement with Zentiva for Europe

Zentiva obtains exclusive commercialization rights for linaprazan glurate. Potential milestone payments total up to EUR 220 million plus royalties, targeting severe erosive reflux disease.

July 2 Cinclus Pharma

Cinclus Pharma reached enrollment target in Phase III study

The HEEALING1 study evaluates linaprazan glurate for erosive GERD, with topline results expected in Q4 2026.

June 3 Cinclus Pharma

Cinclus Pharma completes Phase III HEEALING1 patient screening

The trial evaluates linaprazan glurate for erosive GERD, with topline results expected Q4 2026.

Media coverage

September 2 Affärsvärlden

Stockholm stock exchange shows a broad decline

The OMXS30 index falls at lunchtime while sectors and individual companies such as EQT and Volvo Cars are affected by market pessimism.

September 1 The Globe and Mail

Cinclus Pharma Clears Key Phase III Milestone in Erosive GERD Trial

Cinclus Pharma Holding AB ( (SE:CINPHA)) has shared an announcement. Cinclus Pharma has completed the eight-week treatment period for all patients in its pivotal Phase...

August 19 Affärsvärlden

Stockholm stock exchange opens unchanged with major earnings moves

Surgical Science surges 23% after strong quarterly results while Xspray Pharma falls sharply on negative FDA news.

August 18 FinanzNachrichten.de

Cinclus Pharma Holding AB: Interim report Q2 2026 - HEEALING1 Fully Enrolled - Topline Results Expected in Q4 2026

"Enrollment in our first Phase III trial, HEEALING1, is now completed as planned, and we are entering the final step before readout, expected in the...

Never miss news about Cinclus Pharma

Track Cinclus Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.